CA2572451C - Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature - Google Patents

Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature Download PDF

Info

Publication number
CA2572451C
CA2572451C CA2572451A CA2572451A CA2572451C CA 2572451 C CA2572451 C CA 2572451C CA 2572451 A CA2572451 A CA 2572451A CA 2572451 A CA2572451 A CA 2572451A CA 2572451 C CA2572451 C CA 2572451C
Authority
CA
Canada
Prior art keywords
annexin
agent
imaging
derivative
neovasculature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2572451A
Other languages
English (en)
French (fr)
Other versions
CA2572451A1 (en
Inventor
Jan E. Schnitzer
Philip Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Publication of CA2572451A1 publication Critical patent/CA2572451A1/en
Application granted granted Critical
Publication of CA2572451C publication Critical patent/CA2572451C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2572451A 2004-06-02 2005-06-02 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature Expired - Lifetime CA2572451C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57611604P 2004-06-02 2004-06-02
US60/576,116 2004-06-02
PCT/US2005/019399 WO2005117848A2 (en) 2004-06-02 2005-06-02 Vascular targets for detecting, imaging and treating neoplasia or neovasculature

Publications (2)

Publication Number Publication Date
CA2572451A1 CA2572451A1 (en) 2005-12-15
CA2572451C true CA2572451C (en) 2016-05-10

Family

ID=35463318

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2572451A Expired - Lifetime CA2572451C (en) 2004-06-02 2005-06-02 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature

Country Status (7)

Country Link
US (2) US20060024315A1 (https=)
EP (1) EP1755646A2 (https=)
JP (1) JP5139058B2 (https=)
AU (1) AU2005249541B2 (https=)
CA (1) CA2572451C (https=)
TW (1) TWI445525B (https=)
WO (1) WO2005117848A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
NZ569078A (en) * 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
EP2370055A2 (en) * 2008-11-30 2011-10-05 University Of The Witwatersrand, Johannesburg Polymeric pharmaceutical dosage form in sustained release
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
TWI387750B (zh) * 2009-02-10 2013-03-01 Nat Defense Medical Ct Biomarker and detection method for detecting kidney disease
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
WO2012051556A1 (en) * 2010-10-15 2012-04-19 Duke University Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide
EP2691120A4 (en) * 2011-03-31 2014-09-24 Univ Johns Hopkins THEROSTATIC ILLUSTRATION AND USE METHOD THEREFOR
CN102898527B (zh) * 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
WO2018226971A1 (en) * 2017-06-07 2018-12-13 Cedars-Sinai Medical Center Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
GB202019109D0 (en) * 2020-12-03 2021-01-20 Novai Ltd Marker for use in identifying or predicting angiogenesis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
US6180596B1 (en) 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
US20030008819A1 (en) 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
EP0848614B1 (en) 1995-09-08 2006-04-26 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins
US20040115128A1 (en) 1995-09-08 2004-06-17 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
DE69821932T2 (de) 1997-05-30 2004-12-16 Arch Development Corp., Chicago P-selectin translokation ins vaskulare epitheliale lumen durch ionisierende strahlung
JP2001516055A (ja) 1997-09-10 2001-09-25 ザ バーナム インスティチュート 腫瘍中の血管形成血管系にホーミングする分子を同定する方法
CA2219299A1 (en) * 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1157274A1 (en) 1999-03-02 2001-11-28 The University of Dundee Methods of determining altered ndpk functions
AU5472200A (en) 1999-06-17 2001-01-09 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting tumor vasculature
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
DE10017249A1 (de) * 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
JP2004510830A (ja) 2000-10-11 2004-04-08 ターゲサム・インコーポレーテッド 標的化された治療用薬剤
AU2002217760A1 (en) 2000-10-12 2002-04-22 The University Of Tennessee Research Corporation Targeting drug/gene carriers to irradiated tissue
WO2002076394A2 (en) 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US7666391B2 (en) 2001-06-01 2010-02-23 Burnham Institute For Medical Research Breast homing peptides and methods of identifying same using aminopeptidase P
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US6531655B2 (en) * 2001-06-27 2003-03-11 Stuete Schaltgerate Gmbh & Co. Kg Protective-door handle
US20030162706A1 (en) * 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
EP1646357A4 (en) 2003-06-27 2007-01-10 Diadexus Inc PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005027965A1 (en) * 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1755686A2 (en) 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface

Also Published As

Publication number Publication date
JP5139058B2 (ja) 2013-02-06
WO2005117848A9 (en) 2006-04-27
CA2572451A1 (en) 2005-12-15
WO2005117848A2 (en) 2005-12-15
AU2005249541A1 (en) 2005-12-15
US8715675B2 (en) 2014-05-06
US20110044893A1 (en) 2011-02-24
WO2005117848A3 (en) 2006-06-29
AU2005249541B2 (en) 2010-02-25
TW200602081A (en) 2006-01-16
JP2008501701A (ja) 2008-01-24
EP1755646A2 (en) 2007-02-28
US20060024315A1 (en) 2006-02-02
TWI445525B (zh) 2014-07-21

Similar Documents

Publication Publication Date Title
US8715675B2 (en) Vascular targets for detecting, imaging and treating neoplasia or neovasculature
US6689744B2 (en) Notch receptor agonists and uses
AU2005249540B2 (en) Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
JP2000505787A (ja) 中皮抗原及びそれを標的化するための方法及びキット
JP5847755B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
TW201130512A (en) Methods for the treatment of head and neck squamous cell carcinoma
JP2017505107A (ja) Ｃｃｒ９に対する抗体およびその用途
US20200171165A1 (en) Enhanced targeted delivery of therapeutic agents
US8629247B2 (en) Antibodies against prostate specific membrane antigen
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
JP4365583B2 (ja) ノッチレセプターアゴニスト及び用途
AU2001292750A1 (en) Notch receptor agonists and uses
WO2006068822A1 (en) Notch receptor agonists and uses
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
EP4497755A1 (en) Anti-wnt-11 antibodies
WO2020112129A1 (en) Enhanced targeted delivery of therapeutic agents

Legal Events

Date Code Title Description
EEER Examination request